# US 2010/0137303 A1 · New compound 255

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0137303 A1
- Document ID: US20100137303A1
- Status: Published application
- Kind: A1
- Application number: 12/476,418
- Filed: 2009-06-02
- Published: 2010-06-03
- Earliest claimed: 2008-06-04
- Assignees: AstraZeneca AB
- Inventors: Sandeep Raghunath Ghorpade; Manoj Ganpat Kale; Shahul Hameed Peer Mohamed; Anand Kumar Venkobachar Raichurkar; David Charles McKinney
- Web page: https://patentgrep.com/patent/US20100137303A1

## CPC

- C07D 513/04: Ortho-condensed systems
- A61P 31/04: Antibacterial agents
- C07D 498/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compounds of formula (I) and their pharmaceutically acceptable salts are described. Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described.

## Claims

### Claim 1

A compound of formula (I):
wherein
Y is S or O
Q is C(═O)NR4, C(═S)NR5, C(═O)O, C(═NH)NR6, C(═NCN)NR7, SO2NR8, C(═O)C(═O)NR9, or C═O, SO2;
to R4, R5, R6, R7, R8, R9 are independently selected from H, OH, C1-4alkyl, and C3-6 cycloalkyl;
R1 is C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxy, C1-6haloalkyl, C1-6haloalkoxy, C3-7 cycloalkyl, aryl, aryl C1-6alkyl or heterocyclyl.
X is N or CRa wherein Ra is H, F, CH3, OCH3, CN;
m=0 to 5
Ring A is a carbocyclic or heterocyclic ring system comprising up to 12 ring atoms and up to 5 heteroatoms each independently selected from N, O and S; wherein if said heterocyclyl contains an —NH— moiety that nitrogen may be optionally substituted by a group R10;
R3 is hydrogen, halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxy, C1-6alkanoyl, C1-6alkanoyloxy, N-(C1-6alkyl)amino, N,N-(C1-6alkyl)2amino, C1-6alkanoylamino, N-(C1-6alkyl)carbamoyl, N,N-(C1-6alkyl)2carbamoyl, N-(C1-6alkoxy)carbamoyl, N,N-(C1-6alkoxy)2carbamoyl, C1-6alkylS(O)a wherein a is 0 to 2, C1-6alkoxycarbonyl, C1-6alkoxycarbonylamino, N-(C1-6alkyl)sulphamoyl, N,N-(C1-6alkyl)2sulphamoyl, C1-6alkylsulphonylamino, carbocyclyl-R11— or heterocyclyl-R12—; wherein R3 may be optionally substituted on carbon by one or more R13; and wherein if said heterocyclyl contains an —NH— moiety that nitrogen may be optionally substituted by a group selected from R14;
substituents on carbon are independently selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxy, C1-6alkanoyl, C1-6alkanoyloxy, N-(C1-6alkyl)amino, N,N-(C1-6alkyl)2amino, C1-6alkanoylamino, N-(C1-6alkyl)carbamoyl, N,N-(C1-6alkyl)2carbamoyl, N-(C1-6alkoxy)carbamoyl, N,N-(C1-6alkoxy)2carbamoyl, C1-6alkylS(O)a wherein a is 0 to 2, C1-6alkoxycarbonyl, C1-6alkoxycarbonylamino, N-(C1-6alkyl)sulphamoyl, N,N-(C1-6alkyl)2sulphamoyl, C1-6alkylsulphonylamino, carbocyclyl-R15— or heterocyclyl-R16—; and wherein if said heterocyclyl contains an —NH— moiety that nitrogen may be optionally substituted by a group selected from R17;
to and wherein R3 may be directly attached to the C5 position of thiazolopyridine or oxazolopyrdine without ring A, in which case R3 is halogen, cyano, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxy, C1-6haloalkyl, C1-6haloalkoxy, C3-7 cycloalkyl, C3-7 cycloalkoxy, N-(C1-6alkyl)amino, N,N-(C1-6alkyl)2amino, N-(C1-6alkyl)amino alkoxy, N,N-(C1-6alkyl)2amino alkoxy, heterocycloalkoxy with 1-5 heteroatoms in it, arylalkoxy, heterocycloalkyl, arylalkyl, N-(C1-6alkyl)aminoalkoxy, N,N-(C1-6alkyl)2aminoalkoxy, C1-6alkylS(O)a wherein a is 0 to 2, C1-6alkoxycarbonyl, C1-6alkoxycarbonylamino, N-(C1-6alkyl)sulphamoyl, N,N-(C1-6alkyl)2sulphamoyl, C1-6alkylsulphonylamino.
R11, R15 and R16 are independently selected from a direct bond, —O—, —N(R18)—, —C(O)—, —N(R19)C(O)—, —C(O)N(R20)—, —S(O)s—, —SO2N(R21)— or —N(R22)SO2—; wherein R18, R19, R20, R21 and R22 are independently selected from hydrogen or C1-6alkyl and s is 0-2; and
R10, R14 and R17 are independently selected from C1-6alkyl, C3-6cycloalkyl, C1-6alkanoyl, C1-6alkylsulphonyl, C1-6alkoxycarbonyl, carbamoyl, N-(C1-6alkyl)carbamoyl, N,N-(C1-6alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl;
R13 and R12 are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, N,N-dimethylcarbamoyl, N,N-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulphamoyl, N-ethylsulphamoyl, N,N-dimethylsulphamoyl, N,N-diethylsulphamoyl or N-methyl-N-ethylsulphamoyl;
R2 is H, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxy, C1-6haloalkyl, C1-6haloalkoxy, C3-7 cycloalkyl, C3-7 cycloalkoxy, N-(C1-6alkyl)amino, N,N-(C1-6alkyl)2amino, N-(C1-6alkyl)amino alkoxy, N,N-(C1-6alkyl)2amino alkoxy, heterocycloalkoxy with 1-5 heteroatoms in it, arylalkoxy, heterocycloalkyl, arylalkyl, N-(C1-6alkyl)aminoalkoxy, N,N-(C1-6alkyl)2aminoalkoxy, C1-6alkylS(O)a wherein a is 0 to 2, C1-6alkoxycarbonyl, C1-6alkoxycarbonylamino, N-(C1-6alkyl)sulphamoyl, N,N-(C1-6alkyl)2sulphamoyl, or C1-6alkylsulphonylamino, or
R2 is a group
wherein
Z is O, S, or NRb wherein Rb is H, C1-6alkyl, C3-7 cycloalkyl, C1-6alkoxyC1-6alkyl, cycloC3-7alkoxyC1-6alkyl; alternatively Z may represent a heterocyclic ring system comprising up to 7 ring atoms and up to 5 heteroatoms each independently selected from is N, O and S,
alternatively Z is absent and the R2 group is directly attached to the thiazolopyridine or oxazolopyridine ring at the C6 position,
Ring B is a carbocyclic or heterocyclic ring system comprising up to 12 ring atoms and up to 5 heteroatoms each independently selected from N, O and S; and wherein if said ring system contains an —NH— moiety that nitrogen may be optionally substituted by a group R10;
R23 is hydrogen, halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxy, C1-6alkanoyl, C1-6alkanoyloxy, N-(C1-6alkyl)amino, N,N-(C1-6alkyl)2amino, C1-6alkanoylamino, N-(C1-6alkyl)carbamoyl, N,N-(C1-6alkyl)2carbamoyl, N-(C1-6alkoxy)carbamoyl, N,N-(C1-6alkoxy)2carbamoyl, C1-6alkylS(O)a wherein a is 0 to 2, C1-6alkoxycarbonyl, C1-6alkoxycarbonylamino, N-(C1-6alkyl)sulphamoyl, N,N-(C1-6alkyl)2sulphamoyl, C1-6alkylsulphonylamino, carbocyclyl-R11— or heterocyclyl-R12—; wherein the carbocyclyl or heterocyclyl may be optionally substituted on carbon by one or more R13; and wherein if said heterocyclyl contains an —NH— moiety that nitrogen may be optionally substituted by a group R14;
or alternatively Ring B may be absent and R23 is directly attached to —(CH2)m—, in which case R23 is selected from halogen, cyano, C1-6alkyl, C2-6alkenyl, C2-6alkynyl C1-6alkoxy, C1-6haloalkyl, C1-6haloalkoxy, C3-7 cycloalkyl, C3-7 cycloalkoxy, N-(C1-6alkyl)amino, N,N-(C1-6alkyl)2amino, N-(C1-6alkyl)amino alkoxy, N,N-(C1-6alkyl)2amino alkoxy, heterocycloalkoxy with 1-5 heteroatoms in it, arylalkoxy, heterocycloalkyl, arylalkyl, N-(C1-6alkyl)aminoalkoxy, N,N-(C1-6alkyl)2aminoalkoxy, C1-6alkylS(O)a wherein a is 0 to 2, C1-6alkoxycarbonyl, C1-6alkoxycarbonylamino, N-(C1-6alkyl)sulphamoyl, N,N-(C1-6alkyl)2sulphamoyl, C1-6alkylsulphonylamino;
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

A compound of formula I as claimed in claim 1 or a pharmaceutically acceptable salt thereof and wherein Q is any one of C(═O)NH, C(═S)NH, CO, C(═O)C(═O)NH.

### Claim 3 (depends on 1)

A compound of formula I as claimed in claim 1 or a pharmaceutically acceptable salt thereof and wherein R1 is any one of —CH3, CH2CH3, CH(CH3)2, CH2CH(CH3)2, OCH3, CF3CH2, CH2CH═CH2, cyclopropyl, prolinyl, pyrazinyl, pyrimidinyl.

### Claim 4 (depends on 1)

A compound of formula I as claimed in claim 1 or a pharmaceutically acceptable salt thereof and wherein X is any one of CH, CF, N.

### Claim 5 (depends on 1)

A compound of formula I as claimed in claim 1 or a pharmaceutically acceptable salt thereof and wherein Ring A is any one of

### Claim 6 (depends on 1)

A compound of formula I as claimed in claim 1 or a pharmaceutically acceptable salt thereof and wherein R3 is any one of H, F, OCH3, CH3, CF3, CHF2, CN, CH2OCH2CH3, CONH2, COOH, Cl, COCH3

### Claim 7 (depends on 1)

A compound of formula I as claimed in claim 1 or a pharmaceutically acceptable salt thereof and wherein R2 is any one of H, CH3, OCH3, OCH2CH3, OCF3, OCH2CH2═CH2, OCH2CF3

### Claim 8 (depends on 1)

A compound of Formula I as claimed in claim 1 or a pharmaceutically acceptable salt thereof and wherein R2 is represented as
wherein
Z is O, NH, or NCH3, or Z represents a heterocyclic ring system comprising up to 7 ring atoms and up to 3 heteroatoms each independently selected from N, O and S,
alternatively Z is absent and the R2 group is directly attached to the thiazolopyridine or oxazolopyridine ring at the C6 position,
Ring B is selected from one of
R23 is H, F, OCH3, OC2H5, OC(CH3)2, OCH2CH═CH2, OCH2CF3, CH3, CF3, CHF2, CH2OCH2CH3, CONH2, COOH, Cl, COCH3

### Claim 9 (depends on 1)

A process for preparing a compound of formula I or a pharmaceutically acceptable salt thereof as claimed in claim 1, which process comprises:
a) reacting an amine of the formula (IIa) or (IIb):
wherein Z is halogen and R1 has the meaning stated in claim 1
with an isocyanate of formula (IIIa) or an activated derivative of formula (IIIb)
wherein Y is a displaceable group and R1 and Q have the meanings stated in claim 1, in the presence of a suitable base and solvent to give a compound of formula (IVa) or (IVb)
b) reacting boronic acid or boronate ester of the formula (V)
wherein R3, A, R7, n and m are as defined in relation to Formula I,
with a compound of formula (IVa) or (IVb) as shown above n the presence of a suitable palladium (0) catalyst to give a compound of formula I as shown above
and
after process a) or b) above, if required doing one or more of the following:
i) converting a compound of the formula (I) into another compound of the formula (I);
ii) removing any protecting groups;
iii) forming a pharmaceutically acceptable salt.

### Claim 10 (depends on 1)

A compound of the formula I as claimed in claim 1 or a pharmaceutically-acceptable salt thereof for use in a method of treatment of the human or animal body by therapy.

### Claim 11 (depends on 1)

Use of a compound of the formula I as claimed in claim 1 or a pharmaceutically-acceptable salt thereof in the preparation of a medicament for the treatment of the human or animal body by therapy.

### Claim 12 (depends on 1)

A method of treating a bacterial infection in an animal in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof as defined in claim 1.

### Claim 13 (depends on 1)

A pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof as defined in claim 1 together with a pharmaceutically acceptable diluent or carrier.
